Pathogens are loose in America since Trump returned to the White House

The numbers arrived quietly, without fanfare, without alarm—just another data set buried in a government spreadsheet. But to those who know how to read such things, they told a story that should have stopped the country cold.

In the first two months of 2026, more than 1,100 Americans contracted measles. That is six times the normal rate for that period. And that is just measles.

The Pan American Health Organization will convene on April 13 to decide whether the United States should be stripped of its measles elimination status—a certification it has held since the disease was declared vanquished in this country a quarter-century ago.

The question, to anyone paying attention, is not whether that will happen, but whether anyone in Washington will notice when it does.

The answer, if the past year is any guide, is probably not.

Something has happened to America’s public health apparatus. It did not collapse in a single dramatic moment, with sirens and flashing lights. It was dismantled, piece by piece, in the cold bureaucratic language of budget reconciliations and personnel actions and the quiet deletion of web pages.

More than 4,400 people have left the National Institutes of Health—roughly one of every five who were there when the year began. Thousands more have departed the Centers for Disease Control and Prevention. Those who remain have been instructed, in some cases, to keep their heads down and not look too closely at what might be spreading.

What is spreading, it turns out, is quite a lot.

In Nevada, a dairy worker contracted bird flu from an infected cow. In Ohio, a poultry worker was hospitalized with the same virus. In Wyoming, the owner of a backyard flock fell so ill that doctors had to reach deep into his lungs for a specimen that would confirm what was killing him.

The virus that infected him carried a mutation—E627K in the polymerase basic 2 protein—that scientists have long known makes influenza replicate more efficiently in mammalian cells.

Seventy confirmed human cases of H5N1 have been documented since April 2024. But that number, like so many others, comes with an asterisk. With surveillance systems hobbled and agricultural workers often reluctant to come forward, the true count is almost certainly higher.

The virus is spreading cow-to-cow now. Cow-to-human has been documented. The only thing standing between this virus and the next pandemic is a roll of the genetic dice. And the people who used to watch that dice game for a living have been told to find other work.

Tuberculosis, that old companion of tenement housing and frontier poverty, has returned to polite conversation.

More than 10,000 cases were confirmed in 2024 and 2025—an increase after decades of steady decline.

The disease clusters in places where the rent is cheap and the public health clinics are understaffed. It lingers in lungs and waits. And now, with research grants canceled and screening programs disrupted, it waits with less interference than it once faced.

The numbers tell a stark story.

At the NIH alone, roughly 2,400 research grants have been terminated.

Among them were 97 grants for infectious disease research—14 percent of all such funding. Clinical trials involving more than 74,000 patients have been shuttered midstream, leaving those enrolled not only without treatment but with a profound suspicion of the institutions that recruited them.

The Pediatric Brain Tumor Consortium, established in 1999, lost its funding without explanation. Eight studies were open and enrolling when the money stopped. Children with ependymoma—a cancer that often laughs at chemotherapy—were in the middle of a phase 1 trial for CAR T-cell therapy when the grinding halt came. The study is now closed to new patients.

Across the government, the story repeats. The CDC’s FoodNet system, which tracked foodborne pathogens like campylobacter and listeria and cyclospora, has seen its surveillance reduced.

The Morbidity and Mortality Weekly Report—for decades the gold standard of public health communication—lost the very writers who produced it, before some were hastily rehired when someone noticed the coding error.

The United States has begun the process of withdrawing from the World Health Organization. The sharing of global influenza data, which depends on precisely the kind of international cooperation that such membership facilitates, has become less certain.

And the diseases that Americans once thought belonged to other places, other climates, other centuries, have been quietly establishing residence.

Chagas disease, transmitted by the so-called “kissing bug” that bites sleeping faces and defecates near the wound, has now been found in 32 states.

The Centers for Disease Control estimates that 280,000 Americans carry the parasite. Left untreated—and it often is, because few physicians think to test for it—it can lead to heart failure, stroke, and death years after the initial infection.

Leprosy. Dengue. Lymphatic filariasis. These are not words that belonged in American public health briefings a decade ago. They belong there now.

The response, such as it is, has been piecemeal and improvisational. Several states—California, New York, and Illinois, among them—have formed their own alliances and reached directly to the World Health Organization for guidance. They track outbreaks themselves. They promote vaccine access themselves. They do, in other words, what the federal government used to do for them.

But states cannot replace the National Institutes of Health. They cannot rebuild the CDC’s disease surveillance networks.

They cannot restore the 1,000 pages of infectious disease information that were removed from federal websites.

They cannot rehire the scientists who have fled to Europe or Canada or the Netherlands, where research funding does not vanish because a bureaucrat in Washington decided that “diversity, equity, and inclusion” were unacceptable words.

In January, the Department of Health and Human Services announced changes to the childhood immunization schedule, aligning it more closely with the practices of other developed nations.

The new schedule recommends vaccines for measles, mumps, rubella, polio, and pertussis—the usual suspects. It leaves other vaccines to “shared clinical decision-making” between doctors and parents.

The announcement noted, almost as an aside, that public trust in health care institutions had declined significantly between 2020 and 2024. It noted that childhood vaccination rates had fallen. It noted that the risk of vaccine-preventable diseases had increased.

It did not note the irony.

In Mali, a woman named Diango Tounkara recently learned that the program which treated her trachoma—and the program where she worked for two decades distributing drugs to prevent neglected tropical diseases—had been shut down. American funding had paid for those programs.

American funding had helped eliminate trachoma in her country. American funding had been cut without warning, leaving health officials scrambling and communities wondering what would come next.

“I felt totally deceived,” she told a reporter.

That sentiment is not confined to Mali.

In Chicago, a clinical trial examining whether counseling could prevent depression and reduce HIV transmission in young stimulant users was halted midstream. The Adolescent Medicine Trials Network for HIV Interventions had been operating since 2001. Its $17 million in grants were terminated. The participants, many of them young and already distrustful of medical institutions, were told to go home.

“The harms to the communities we serve—being cut off from trials, from relationships with research teams and institutions—and the increased mistrust in research that abrupt terminations caused is the most palpable damage, and the hardest piece to rebuild,” said Sybil Hosek, one of the network’s directors.

The question that hangs over all of this—over the measles outbreaks and the bird flu mutations and the clinical trials that will never finish—is whether anyone is still watching.

The CDC continues to publish estimates of the reproductive number for various diseases, tracking whether infections are growing or declining state by state. As of February 3, COVID-19 was growing or likely growing in 13 states. Influenza in 9. RSV in 24.

These are the numbers that used to prompt action. Now they simply exist, updated weekly on a website, waiting for someone to notice that the line has crossed into the red.

The administration announced in January a $50 billion investment in rural health, spread over five years, to transform access and promote innovation. It was the largest such investment in history, according to the press release.

But money alone does not rebuild what has been dismantled. It does not restore the scientists who have left. It does not rebuild trust with communities that have been abandoned mid-trial. It does not track the next mutation of H5N1 or detect the next foodborne outbreak before it sickens hundreds.

The boulder that Sisyphus pushed up the hill—the long, grinding work of eliminating neglected tropical diseases, of controlling infectious outbreaks, of building a public health system that protects everyone—has rolled back down. It will take a generation to push it up again.

The question is what happens in the meantime.

The viruses, bacteria, and parasites are not waiting.

They do not respect budget cycles, personnel actions, or changes in administration. They do not care about the decline in public trust or the deletion of web pages. They simply do what they have always done: look for the next host, the next opportunity, the next crack in the defenses.

And the defenses, after the past year, have more cracks than they have had in a very long time.